---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-156440"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2025-07-08T23:59:59+00:00"
generated_at: "2026-05-18T09:05:44.650297+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Recursion acquires full ownership of oral ENPP1 inhibitor program from Rallybio

## Summary
- Buys Rallybio's 50% stake in ENPP1 JV, gaining full rights to REV102 for hypophosphatasia.
- Initial consideration: 1,457,952 RXRX shares (~$7.5M at $5.1442 VWAP) plus cash.
- Contingent milestone payments up to $12.5M in additional shares.
- REV102 is a preclinical oral ENPP1 inhibitor for rare bone disorder HPP.
- Deal closed July 8, 2025; resale registration filed for issued shares.

## SEC filing metadata
- accession: 0001193125-25-156440
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2025-07-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000119312525156440/0001193125-25-156440-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000119312525156440/d83626d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-156440
- JSON: https://secwatch.observer/filing/0001193125-25-156440.json
- Plain text: https://secwatch.observer/filing/0001193125-25-156440.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.